AI assistant
ELI LILLY & Co — Director's Dealing 2018
Jun 1, 2018
29745_dirs_2018-06-01_40cc9e00-e064-4c37-a930-71bc6e71a9ca.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: LILLY ELI & CO (LLY)
CIK: 0000059478
Period of Report: 2018-05-29
Reporting Person: Shaw Christi (SVP and Pres., Lilly Bio-Meds)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-05-29 | Common Stock | S | 8426 | $82.10 | Disposed | 0 | Direct |
Footnotes
F1: This amendment is being filed to add footnotes to the transaction.
F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 26, 2018.
F3: This transaction was executed in multiple trades at prices ranging from $81.73 to $82.10. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.